JP2021533795A5 - - Google Patents
Info
- Publication number
- JP2021533795A5 JP2021533795A5 JP2021509223A JP2021509223A JP2021533795A5 JP 2021533795 A5 JP2021533795 A5 JP 2021533795A5 JP 2021509223 A JP2021509223 A JP 2021509223A JP 2021509223 A JP2021509223 A JP 2021509223A JP 2021533795 A5 JP2021533795 A5 JP 2021533795A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- aav
- gpr108
- polypeptide
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862720859P | 2018-08-21 | 2018-08-21 | |
| US62/720,859 | 2018-08-21 | ||
| PCT/US2019/047546 WO2020041498A1 (en) | 2018-08-21 | 2019-08-21 | Compositions and methods for modulating transduction efficiency of adeno-associated viruses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021533795A JP2021533795A (ja) | 2021-12-09 |
| JP2021533795A5 true JP2021533795A5 (enExample) | 2022-07-25 |
| JP7451497B2 JP7451497B2 (ja) | 2024-03-18 |
Family
ID=69591093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021509223A Active JP7451497B2 (ja) | 2018-08-21 | 2019-08-21 | アデノ随伴ウイルスの形質導入効率を調節するための組成物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12195745B2 (enExample) |
| EP (1) | EP3841109A4 (enExample) |
| JP (1) | JP7451497B2 (enExample) |
| AU (1) | AU2019325332B2 (enExample) |
| WO (1) | WO2020041498A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3100006A1 (en) | 2018-05-11 | 2019-11-14 | Massachusetts Eye And Ear Infirmary | Altering tissue tropism of adeno-associated viruses |
| CA3153972A1 (en) | 2019-09-09 | 2021-03-18 | Massachusetts Eye And Ear Infirmary | Methods and compositions for modulating the interaction between adeno-associated virus (aav) and the aav receptor (aavr) for altered bio-distribution of aav |
| AU2021251429B2 (en) | 2020-04-09 | 2025-12-18 | University Of Sheffield | Gene therapy treatment |
| EP4244365A4 (en) * | 2020-11-10 | 2024-10-16 | The Children's Hospital Of Philadelphia | Compositions and methods for in vivo gene transfer |
| GB202215198D0 (en) | 2022-10-14 | 2022-11-30 | Univ Sheffield | Gene therapy treatment |
| WO2025114699A1 (en) | 2023-11-30 | 2025-06-05 | Cytomos Limited | Cell selection |
| US20250276095A1 (en) | 2024-03-04 | 2025-09-04 | Kate Therapeutics, Inc. | Adeno-associated virus compositions for the treatment of duchenne muscular dystrophy |
| CN118207258A (zh) * | 2024-03-12 | 2024-06-18 | 浙江恒驭生物科技有限公司 | 一种检测腺相关病毒转导滴度的敏感细胞系、构建方法及其应用 |
| WO2025226842A1 (en) | 2024-04-24 | 2025-10-30 | Kate Therapeutics, Inc. | Expression control by drg-expressed mirnas |
| WO2025226841A1 (en) | 2024-04-24 | 2025-10-30 | Kate Therapeutics, Inc. | Gene therapy approach for treating disorders associated with tnnt2 |
| WO2026011008A1 (en) | 2024-07-02 | 2026-01-08 | Kate Therapeutics, Inc. | Expression control by skeletal muscle-expressed mirnas |
| WO2026011009A1 (en) | 2024-07-02 | 2026-01-08 | Kate Therapeutics, Inc. | Compositions and methods for muscle disorders |
| WO2026030242A1 (en) | 2024-07-29 | 2026-02-05 | Kate Therapeutics, Inc. | Adeno-associated virus compositions for the treatment of facioscapulohumeral muscular dystrophy |
| WO2026030244A1 (en) | 2024-07-30 | 2026-02-05 | Kate Therapeutics, Inc. | Adeno-associated virus compositions for the treatment of limb girdle muscular dystrophy 2a |
| WO2026050402A1 (en) | 2024-08-29 | 2026-03-05 | Kate Therapeutics, Inc. | Liver de-targeted muscle tropic capsids |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6855314B1 (en) * | 2000-03-22 | 2005-02-15 | The United States Of America As Represented By The Department Of Health And Human Services | AAV5 vector for transducing brain cells and lung cells |
| WO2003042361A2 (en) | 2001-11-09 | 2003-05-22 | Government Of The United States Of America, Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| SI1496944T1 (sl) * | 2002-05-01 | 2009-02-28 | Univ Florida | Izboljšani sistemi ekspresije RAAV za genetsko modifikacijo specifičnih kapsidnih proteinov |
| US20060166363A1 (en) * | 2004-01-27 | 2006-07-27 | Sergei Zolotukhin | Modified baculovirus expression system for production of pseudotyped rAAV vector |
| ES2525067T3 (es) * | 2005-04-07 | 2014-12-17 | The Trustees Of The University Of Pennsylvania | Método de incremento de la función de un vector de AAV |
| US9567376B2 (en) | 2013-02-08 | 2017-02-14 | The Trustees Of The University Of Pennsylvania | Enhanced AAV-mediated gene transfer for retinal therapies |
| CN107073051B (zh) * | 2014-10-21 | 2021-08-24 | 马萨诸塞大学 | 重组aav变体及其用途 |
| US10081659B2 (en) * | 2015-04-06 | 2018-09-25 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Adeno-associated vectors for enhanced transduction and reduced immunogenicity |
| US10633662B2 (en) | 2015-11-10 | 2020-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for modulating AAV infection |
| EP3448874A4 (en) * | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| US11364308B2 (en) * | 2016-05-13 | 2022-06-21 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and methods of use thereof |
| IL305149A (en) | 2016-07-26 | 2023-10-01 | Biomarin Pharm Inc | Novel adeno-associated virus capsid proteins |
| CA3033856A1 (en) * | 2016-08-15 | 2018-02-22 | Genzyme Corporation | Methods for detecting aav |
| WO2018119330A2 (en) * | 2016-12-22 | 2018-06-28 | Oregon Health & Science University | Adeno associated viral vectors |
| US20210292373A1 (en) | 2018-07-10 | 2021-09-23 | University Of Florida Research Foundation, Incorporated | Aav vp1u chimeras |
| TW202532428A (zh) * | 2019-04-26 | 2025-08-16 | 美商愛德維仁生物科技公司 | 用於玻璃體內遞送之變異體aav蛋白殼 |
-
2019
- 2019-08-21 WO PCT/US2019/047546 patent/WO2020041498A1/en not_active Ceased
- 2019-08-21 JP JP2021509223A patent/JP7451497B2/ja active Active
- 2019-08-21 US US17/269,955 patent/US12195745B2/en active Active
- 2019-08-21 EP EP19851371.5A patent/EP3841109A4/en active Pending
- 2019-08-21 AU AU2019325332A patent/AU2019325332B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021533795A5 (enExample) | ||
| US12534717B2 (en) | AAV capsid proteins for nucleic acid transfer | |
| JP7395550B2 (ja) | 新規アデノ随伴ウイルスキャプシドタンパク質 | |
| JP2022190081A5 (enExample) | ||
| Kohlbrenner et al. | Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system | |
| JP2020019772A5 (enExample) | ||
| IL317938A (en) | Recombinant viral vectors with altered tropism and their uses for the targeted introduction of genetic material into human cells | |
| JP2020532981A5 (enExample) | ||
| KR20250025387A (ko) | Aav 캡시드 변이체 및 이의 용도 | |
| JP2020519284A5 (enExample) | ||
| CA2329060A1 (en) | Aav5 vector and uses thereof | |
| JP2022524434A5 (enExample) | ||
| JP2022525302A5 (enExample) | ||
| US20240269161A1 (en) | Methods and compositions for tau reduction gene therapy | |
| KR20250007619A (ko) | 신규 재조합 aav vp2 융합 폴리펩티드 | |
| JP2020533973A (ja) | 改変されたホスホリパーゼドメインを含むアデノ随伴ウイルス（ａａｖ） | |
| JP2020519294A5 (enExample) | ||
| JP2025004107A (ja) | ガラクトース血症の処置のための遺伝子治療 | |
| JP2024509251A5 (enExample) | ||
| US20240318198A1 (en) | Gene therapy for angelman syndrome | |
| RU2024111148A (ru) | Вирусные частицы, перенацеленные на скелетные мышцы | |
| EP4671264A1 (en) | AAV PLASMIDES COMPRISING AN ACCESSORY PROTEIN CODING SEQUENCE | |
| HK40048783A (en) | New avv capsid proteins for nucleic acid transfer | |
| AR129387A1 (es) | Composiciones y métodos para el tratamiento de deficiencias auditivas no asociadas a la edad en un sujeto humano | |
| RU2019143489A (ru) | УСИЛИВАЮЩИЕ АГЕНТЫ ДЛЯ ПОВЫШЕНИЯ ТРАНСФЕКЦИИ КЛЕТОК И/ИЛИ ПРОДУКЦИИ ВЕКТОРА rAAV |